REFERENCES
1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
2. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
3. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-47.
4. Pegram MD. Treating the HER2 pathway in early and advanced breast cancer. Hematol Oncol Clin North Am 2013;27:751-65, viii.
6. Goutsouliak K, Veeraraghavan J, Sethunath V, et al. Towards personalized treatment for early stage HER2-positive breast cancer. Nat Rev Clin Oncol 2020;17:233-50.
8. Jordan VC. 50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened? Endocr Relat Cancer 2021;28:R11-30.
9. Ma CX, Reinert T, Chmielewska I, Ellis MJ. Mechanisms of aromatase inhibitor resistance. Nat Rev Cancer 2015;15:261-75.
10. Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012;17:1-16.
11. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014;25:282-303.
12. Reinert T, Matsunuma R, Han A, Ellis MJ. Endocrine Therapy in Clinical Practice. Estrogen Receptor and Breast Cancer :2019. p. 215-40.
13. Abderrahman B, Jordan VC. A novel strategy to improve women’s health: selective estrogen receptor modulators. Estrogen Receptor and Breast Cancer. Humana Press, Cham; 2019. p. 189-213
14. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell 2020;37:496-513.
15. Abderrahman B, Jordan VC. The first targeted therapy to treat cancer: the tamoxifen tale. Estrogen Receptor and Breast Cancer. Humana Press, Cham; 2019. p. 151-88
16. Eisen A, Trudeau M, Shelley W, Messersmith H, Pritchard KI. Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: a systematic review. Cancer Treat Rev 2008;34:157-74.
17. Deeks ED. Fulvestrant: a review in advanced breast cancer not previously treated with endocrine therapy. Drugs 2018;78:131-7.
18. Fu X, De Angelis C, Veeraraghavan J, Osborne CK, Schiff R. Molecular mechanisms of endocrine resistance. Estrogen Receptor and Breast Cancer. Humana Press, Cham; 2019. p. 265-307
19. Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 2018;34:427-438.e6.
20. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
21. Formisano L, Stauffer KM, Young CD, et al. Association of FGFR1 with ERα maintains ligand-independent ER Transcription and mediates resistance to estrogen deprivation in ER+ breast cancer. Clin Cancer Res 2017;23:6138-50.
22. Fox EM, Miller TW, Balko JM, et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 2011;71:6773-84.
23. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 2011;13:R21.
24. Miller TW, Hennessy BT, González-Angulo AM, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13.
25. Fu X, Creighton CJ, Biswal NC, et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res 2014;16:430.
26. André F, Ciruelos E, Rubovszky G, et al. SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med 2019;380:1929-40.
27. Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9.
28. Neven P, Sonke GS, Jerusalem G. Ribociclib plus fulvestrant in the treatment of breast cancer. Expert Rev Anticancer Ther 2021;21:93-106.
29. Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925-36.
30. Chong QY, Kok ZH, Bui NL, et al. A unique CDK4/6 inhibitor: current and future therapeutic strategies of abemaciclib. Pharmacol Res 2020;156:104686.
31. Arena C, Bizzoca ME, Caponio VCA, et al. Everolimus therapy and sideeffects: A systematic review and meta-analysis. Int J Oncol 2021;59:54.
32. Spring LM, Zangardi ML, Moy B, Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 Inhibitors in breast cancer: practical considerations and recommendations. Oncologist 2017;22:1039-48.
33. Portman N, Alexandrou S, Carson E, et al. Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer. Endocr Relat Cancer 2019;26:R15-30.
34. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007;18:977-84.
35. Kunte S, Abraham J, Montero AJ. Novel HER2-targeted therapies for HER2-positive metastatic breast cancer. Cancer 2020;126:4278-88.
36. Burguin A, Diorio C, Durocher F. Breast cancer treatments: updates and new challenges. J Pers Med 2021;11:808.
37. Testa U, Castelli G, Pelosi E. Breast cancer: a molecularly heterogenous disease needing subtype-specific treatments. Med Sci (Basel) 2020;8:18.
38. Murthy RK, Loi S, Okines A, et al. Tucatinib, trastuzumab, and capecitabine for her2-positive metastatic breast cancer. N Engl J Med 2020;382:597-609.
39. Isakoff SJ, Baselga J. Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2011;29:351-4.
40. Pegram MD, Miles D, Tsui CK, Zong Y. HER2-overexpressing/amplified breast cancer as a testing ground for antibody-drug conjugate drug development in solid tumors. Clin Cancer Res 2020;26:775-86.
42. Jerusalem G, Lancellotti P, Kim SB. HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. Breast Cancer Res Treat 2019;177:237-50.
43. Dang C, Guo H, Najita J, et al. Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer. JAMA Oncol 2016;2:29-36.
45. Li X, Xu Y, Ding Y, et al. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer. Mol Cancer 2018;17:113.
46. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28.
47. Browne BC, Crown J, Venkatesan N, et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol 2011;22:68-73.
48. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to trastuzumab in breast cancer. Clin Cancer Res 2009;15:7479-91.
49. Bick G, Zhao D, Zhang X. Estrogen receptor-mediated gene transcription and cistrome. Estrogen Receptor and Breast Cancer. Humana Press, Cham; 2019. p. 49-70
50. Yi P, Wang Z, O’malley BW. Structural Studies with Coactivators for the Estrogen Receptor. Estrogen Receptor and Breast Cancer. Humana Press, Cham; 2019. p. 71-93
51. Liu Z, Merkurjev D, Yang F, et al. Enhancer activation requires trans-recruitment of a mega transcription factor complex. Cell 2014;159:358-73.
52. Yi P, Wang Z, Feng Q, et al. Structural and functional impacts of ER coactivator sequential recruitment. Mol Cell 2017;67:733-743.e4.
53. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 2000;14:121-41.
54. Roeder RG. 50+ years of eukaryotic transcription: an expanding universe of factors and mechanisms. Nat Struct Mol Biol 2019;26:783-91.
55. Yang Y, Leonard M, Luo Z, et al. Functional cooperation between co-amplified genes promotes aggressive phenotypes of HER2-positive breast cancer. Cell Rep 2021;34:108822.
56. Kang YK, Guermah M, Yuan CX, Roeder RG. The TRAP/Mediator coactivator complex interacts directly with estrogen receptors alpha and beta through the TRAP220 subunit and directly enhances estrogen receptor function in vitro. Proc Natl Acad Sci U S A 2002;99:2642-7.
57. Malik S, Roeder RG. The metazoan Mediator co-activator complex as an integrative hub for transcriptional regulation. Nat Rev Genet 2010;11:761-72.
58. Li W, Hu Y, Oh S, et al. Condensin I and II complexes license full estrogen receptor α-dependent enhancer activation. Mol Cell 2015;59:188-202.
59. Sabari BR, Dall’Agnese A, Boija A, et al. Coactivator condensation at super-enhancers links phase separation and gene control. Science 2018;361:eaar3958.
60. Lee R, Kang MK, Kim YJ, et al. CTCF-mediated chromatin looping provides a topological framework for the formation of phase-separated transcriptional condensates. Nucleic Acids Res 2022;50:207-26.
61. Zamudio AV, Dall’Agnese A, Henninger JE, et al. Mediator condensates localize signaling factors to key cell identity genes. Mol Cell 2019;76:753-766.e6.
62. Fullwood MJ, Liu MH, Pan YF, et al. An oestrogen-receptor-alpha-bound human chromatin interactome. Nature 2009;462:58-64.
63. Lai F, Orom UA, Cesaroni M, et al. Activating RNAs associate with Mediator to enhance chromatin architecture and transcription. Nature 2013;494:497-501.
64. Li W, Notani D, Ma Q, et al. Functional roles of enhancer RNAs for oestrogen-dependent transcriptional activation. Nature 2013;498:516-20.
65. Chen Z, Zhang C, Wu D, et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J 2011;30:2405-19.
66. Palacio M, Taatjes DJ. Merging established mechanisms with new insights: condensates, hubs, and the regulation of RNA polymerase II transcription. J Mol Biol 2022;434:167216.
67. Tsai KL, Yu X, Gopalan S, et al. Mediator structure and rearrangements required for holoenzyme formation. Nature 2017;544:196-201.
68. Schier AC, Taatjes DJ. Structure and mechanism of the RNA polymerase II transcription machinery. Genes Dev 2020;34:465-88.
69. Zhang H, Chen DH, Mattoo RUH, et al. Mediator structure and conformation change. Mol Cell 2021;81:1781-1788.e4.
70. Schilbach S, Hantsche M, Tegunov D, et al. Structures of transcription pre-initiation complex with TFIIH and Mediator. Nature 2017;551:204-9.
71. Zhu Y, Qi C, Jain S, et al. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci U S A 1999;96:10848-53.
72. Leonard M, Zhang X. Estrogen receptor coactivator mediator subunit 1 (MED1) as a tissue-specific therapeutic target in breast cancer. J Zhejiang Univ Sci B 2019;20:381-90.
73. Jacot W, Fiche M, Zaman K, Wolfer A, Lamy PJ. The HER2 amplicon in breast cancer: topoisomerase IIA and beyond. Biochim Biophys Acta 2013;1836:146-57.
74. Luoh S. Amplification and expression of genes from the 17q11~q12 amplicon in breast cancer cells. Cancer Genetics and Cytogenetics 2002;136:43-7.
75. Zhang X, Krutchinsky A, Fukuda A, et al. MED1/TRAP220 exists predominantly in a TRAP/ Mediator subpopulation enriched in RNA polymerase II and is required for ER-mediated transcription. Mol Cell 2005;19:89-100.
76. Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997;387:733-6.
77. Savkur RS, Burris TP. The coactivator LXXLL nuclear receptor recognition motif. J Pept Res 2004;63:207-12.
78. Plevin MJ, Mills MM, Ikura M. The LxxLL motif: a multifunctional binding sequence in transcriptional regulation. Trends Biochem Sci 2005;30:66-9.
79. Coulthard VH, Matsuda S, Heery DM. An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. J Biol Chem 2003;278:10942-51.
80. Jiang P, Hu Q, Ito M, et al. Key roles for MED1 LxxLL motifs in pubertal mammary gland development and luminal-cell differentiation. Proc Natl Acad Sci U S A 2010;107:6765-70.
81. Yang Y, Leonard M, Zhang Y, et al. HER2-driven breast tumorigenesis relies upon interactions of the estrogen receptor with coactivator MED1. Cancer Res 2018;78:422-35.
82. Cui J, Germer K, Wu T, et al. Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res 2012;72:5625-34.
83. Lupien M, Meyer CA, Bailey ST, et al. Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance. Genes Dev 2010;24:2219-27.
84. Nagalingam A, Tighiouart M, Ryden L, et al. Med1 plays a critical role in the development of tamoxifen resistance. Carcinogenesis 2012;33:918-30.
85. Ross-Innes CS, Stark R, Teschendorff AE, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012;481:389-93.
86. Murtaza M, Dawson SJ, Tsui DW, et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013;497:108-12.
87. Zhang L, Cui J, Leonard M, et al. Silencing MED1 sensitizes breast cancer cells to pure anti-estrogen fulvestrant in vitro and in vivo. PLoS One 2013;8:e70641.
88. Zhang Y, Leonard M, Shu Y, et al. Overcoming tamoxifen resistance of human breast cancer by targeted gene silencing using multifunctional pRNA nanoparticles. ACS Nano 2017;11:335-46.
89. Germer K, Pi F, Guo P, Zhang X. Conjugation of RNA aptamer to RNA nanoparticles for targeted drug delivery. RNA nanotechnology and therapeutics. CRC Press; 2013. p.399-408. Available from: https://www.taylorfrancis.com/chapters/edit/10.1201/b15152-30/conjugation-rna-aptamer-rna-nanoparticles-targeted-drug-delivery-katherine-germer-fengmei-pi-peixuan-guo-xiaoting-zhang [Last accessed on 8 Apr 2022].
91. Jasinski D, Haque F, Binzel DW, Guo P. Advancement of the Emerging Field of RNA Nanotechnology. ACS Nano 2017;11:1142-64.
92. Shu D, Shu Y, Haque F, Abdelmawla S, Guo P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nature Nanotech 2011;6:658-67.
